Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2008-12-15 Board/Management Inform…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Board/Management Information 2008
Board/Management Information Classification · 99% confidence The document is a press release dated December 15, 2008, announcing that the CEO, Lars Adlersson, has informed the board of his wish to resign from his position as CEO of Medivir AB, effective January 31, 2009. This directly concerns a change in senior management. Based on the definitions, this aligns perfectly with the 'Board/Management Information' category.
2008-12-15 Swedish
Report Publication Announcement 2008
Report Publication Announcement Classification · 95% confidence The document is a short press release (604 characters) dated December 10, 2008. The title explicitly states that 'Medivir participates in and presents at Financial Hearings/Avanza Bank's Corporate Day'. It mentions that a webcast of the presentation will be available later on the company website. This structure—a brief announcement about an upcoming or current presentation/event where the company will share information—fits the definition of a Report Publication Announcement (RPA) or potentially an Investor Presentation (IP) if the content was the presentation itself. However, since this text is merely announcing participation and the availability of a future webcast/presentation, it functions primarily as an announcement regarding the release/availability of investor-related material. Given the short length and the focus on announcing participation in an event where a presentation will occur, RPA is the most appropriate classification, as it signals the publication/availability of investor information, even if the actual presentation content is separate.
2008-12-10 Swedish
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a press release dated December 9, 2008, announcing that Medivir received a milestone payment from its collaboration with Tibotec because a preclinical development candidate (CD) was selected in the HCV polymerase project. This announcement details a specific corporate/financial event (receipt of payment due to R&D progress) related to a licensing agreement. It is not a full annual report (10-K), an earnings release (ER), or a formal regulatory filing like a DVA or DIRS. It is a specific update on financing/collaboration progress, which aligns best with the Capital/Financing Update (CAP) category, as it involves a payment triggered by a development milestone under a licensing agreement. Given the nature of the announcement (milestone payment received), CAP is the most appropriate fit over a general Regulatory Filing (RNS).
2008-12-09 Swedish
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a press release dated December 9th, 2008, announcing a specific financial event: receiving a milestone payment of 2.6 million euros from a research collaboration with Tibotec related to hepatitis C drug development. This announcement details a specific financial transaction/achievement outside of routine periodic reporting (like 10-K or IR) or management changes. It is not a full earnings release (ER), which usually covers overall quarterly performance, nor is it a capital raising event (CAP). It is a specific update on a partnership milestone payment, which falls best under a general regulatory/corporate announcement. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for specific, non-standard corporate news updates that don't fit the highly specific categories like DIV, DIRS, or MANG. It is not a Call Transcript (CT), Investor Presentation (IP), or Management Discussion (MDA).
2008-12-09 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a short press release (1019 characters) dated December 8, 2008, announcing that the registration application for the product Lipsovir® has been validated by the US (FDA) and European drug authorities. It details the next steps (review process) and expected timeline (Q3 2009 decision). This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER) or a management discussion (MDA). It concerns a specific regulatory/legal milestone related to product approval. Since it is an announcement about a regulatory process milestone, and it doesn't fit perfectly into LTR (Legal Proceedings Report) or RNS (General Regulatory Filings), I must evaluate the closest fit. Given that it is a specific announcement regarding a regulatory submission/approval process, it is best categorized as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory Update. However, RNS is the designated fallback for miscellaneous regulatory announcements that don't fit elsewhere. Since it is a specific, non-financial, non-management announcement, RNS is the most appropriate general category.
2008-12-08 Swedish
Regulatory Filings 2008
Regulatory Filings Classification · 90% confidence The document is a short press release dated December 8, 2008, announcing that the Marketing Authorization Application (NDA/MAA) for the product Lipsovir® has been validated by the FDA and European authorities, initiating the review process. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER). It relates to regulatory progress for a product, which falls under general regulatory announcements or potentially legal/regulatory updates. Given the context of regulatory submission validation, it is best classified as a general Regulatory Filing (RNS) as it doesn't fit the specific financial or corporate governance codes, and it is an announcement rather than the final decision or a full report. It is too specific for RNS, but since there is no 'Regulatory Approval Update' category, RNS serves as the best fit for a non-financial, non-governance regulatory milestone announcement.
2008-12-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.